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In a recent perspective article, leading scientists from the
Centers for Disease Control and Prevention (CDC) and the
International Center for AIDS Care and Treatment Programs
(ICAP) argue that more data on the individual-level health
benefits and risks associated with immediate initiation of
antiretroviral therapy (ART) in Africa are urgently needed,
before new guidelines for when to start ART in Africa can be
issued [1]. To ‘‘definitively’’ settle the question of when to
start ART in Africa, De Cock and El-Sadr propose a ‘‘large,
simple’’ randomized controlled trial (RCT) that would assess
the health risks and benefits of immediate versus deferred
ART, with key end points that include tuberculosis incidence,
hospitalization and death.
We profoundly disagree with this opinion and argue
that inaction while waiting for the results of such a trial is
unjustified. While we do not oppose an African RCT to better
understand the health benefits and risks of earlier ART
initiation, we make the case for a fundamental shift in
thinking around ART initiation in Africa, centred on the
patient’s right to decide when to start ART, in consultation
with his or her health care providers, and guided by all
scientific evidence, including that from past, on-going and
planned implementation studies.
In sub-Saharan Africa, ART initiation is generally not
recommended in people with more than 350 CD4 cells/
mL unless they are co-infected with TB; but some countries
have expanded ART guidelines to include ART initiation
irrespective of CD4 count for serodiscordant couples
(Zambia and Nigeria), for HIV-positive partners of HIV-
negative pregnant women (Burundi), and for HIV-positive
pregnant and breastfeeding women (Malawi, Uganda and
Zambia). In the United States, national ART guidelines now
recommend ART initiation irrespective of CD4 cell count.
In Europe and several countries in South America, including
Brazil, guidelines stipulate that ART should be offered
to those whose CD4 cell count is less than 500/mL [2,3].
The 2013 World Health Organization’s (WHO) Consolidated
guidelines on the use of antiretroviral drugs for treating
and preventing HIV infection stipulate that ART initiation
is recommended in all individuals with a CD4+ cell count
of 500 cells/mL or less (but giving priority to those with
advanced clinical disease or a CD4+ cell count less than
350 cells/mL); and at any CD4+ cell count in those with active
TB, Hepatitis B infection and severe chronic liver disease,
in HIV-positive partners in serodiscordant couples, and in
pregnant and breastfeeding women.
De Cock and El-Sadr argue that this ‘‘diversity in guidelines
and practice reflects a lack of definitive data indicating
what is best for those who would be taking the drugs.’’ They
further claim that conflicting evidence from observational
studies, absence of data from sub-Saharan Africa and limited
data from randomized trials necessitate the proposed RCT.
Of course, there is scope for refining our understanding
of the risks and benefits of immediate ART initiation, but we
would argue that the diversity in guidelines primarily reflects
differences in the availability of financial resources across
regions, as well as inter-regional differences in countries’
readiness and ability to respond to recent science on the
epidemiological and health economic implications of earlier
ART initiation.
Current understanding of the biological effects of HIV viral
replication and ART, together with an ever-growing evidence
base from (mainly) observational studies, suggest that the
sooner one starts ART, the greater the reduction in morbidity
and mortality in individuals living with HIV [4/7]. More
empirical evidence will become available in the next one
to two years from on-going studies of immediate versus
deferred ART initiation in sub-Saharan Africa. While some of
these are primarily designed to estimate the community-level
impact of earlier ART on HIV incidence, The TEMPRANO RCT
was designed to estimate individual-level benefits and risk
associated with early ART initiation [8]. To wait for additional
evidence from an African RCT that is yet to be designed
and conducted, while observing how other regions have
moved to recommending ART initiation irrespective of CD4
count, based on the available evidence and well in advance
of the results from the START and TEMPRANO trials, seems
inconsistent and ethically questionable.
Moreover, in a recent meta-analysis of studies that
assessed the effect of ART on TB incidence in developing
countries, including the HPTN 052 RCT (where 54% of
participants were from sub-Saharan Africa), ART was strongly
associated with a reduction in tuberculosis incidence in
adults with CD4 counts above 350 cells/mL, with no
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evidence for heterogeneity of effect across the three studies
[9]. New data on the CD4 cell count trajectory during
the first four years after ART initiation show that the odds of
CD4 cell recovery to 900 or more cells/mL within four years
after ART initiation decreases with 10% for each incremental
month of delay between the estimated date of infection
and ART initiation [7] and that ART initiation during primary
HIV infection can delay disease progression [6].
RCTs are most appropriate for investigating efficacy
and safety of new regimens in a well-controlled environment
where neither costs nor efforts are spared to achieve minimal
loss to follow-up. In contrast, the variables to be assessed
when deciding on national or regional ART initiation guide-
lines are large in number, often ill-defined or hard to
measure, and necessarily include indicators of real-life
acceptability, feasibility, affordability and scalability of the
ART initiation policy under consideration.
More urgent than an African RCT, are implementation
studies that document how offering immediate access to ART
initiation, accompanied by additional investments in primary
health care and community-based support, correlate with
changes in HIV testing behaviour, linkage to care, treatment
adherence and retention in care. Furthermore, such studies
could investigate whether immediate access to ART can help
to simplify treatment protocols, contribute to the elimination
of new HIV infections among children, improve economic
productivity and reduce the cost of pre-ART care [10].
We argue that the evidence base is already sufficient
to support a global recommendation for immediate access
to ART, irrespective of CD4 cell count. However, our central
tenet remains that the decision when to start ART should be
made individually by each person living with HIV. Patient-
centred health care does not only mean that patients’ health
and wellbeing is central in the medical decision-making
process but it also means that patients are granted the right
to make an informed choice about if/when they want to start
treatment, even if part of this information is that the benefits
and the risks for individual patients are still unclear at the
moment. Patient-readiness to start ART also requires that
health care providers and community-based organisations
support patients and communities with ART literacy and
preparedness skills. We welcome the new WHO guidelines
and see these as a key step in the direction of offering
immediate treatment to all. It will now be up to individual
countries (Governments, People Living with HIV and Civil
Society) to make informed decisions about when to start
treatment, taking into account the entire evidence base
and human rights considerations, and not primarily base
decisions on RCT data or the (perceived) lack thereof.
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